drugset / Trial / NCT00137852
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Phase 2
Completed
35 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collabPharmacia · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill cancer cells. The primary goal is to develop a well-tolerated cancer treatment that has an acceptable response rate.
Timeline
- Start
- 2002-01
- Primary completion
- 2004-08
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | Cisplatin | Other / unclassified | 30 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 65 mg/m2 | — |